MaaT Pharma (MAAT) Corporate presentation summary

Financial position and strategic priorities

• Cash €17.1m at June 30, 2026; expected cash horizon December 2026 under current operational assumptions.

• Strategic review underway, with financing and strategic options under exploration.

• PHOENIX and MaaT034 development depend on funding; financing opportunities and pharmaceutical partnerships are being explored.

• Estimated peak annual sales for third-line aGvHD: $300m in the U.S. and $70m–$95m in the EU.

Xervyteg in aGvHD

• ARES met its primary endpoint: Day 28 GI-ORR 61.2% (n=67); GI-ORR was 46.3% at Day 56 and 43.3% at Month 3.

• ARES 1-year OS was 54.2% (n=66); Day 28 GI responders had 68% 1-year OS versus 28% for nonresponders.

• CHRONOS reported 28.9% 1-year OS and median OS of 86 days; comparisons with ARES are descriptive, non-randomized and unmatched.

• A negative CHMP opinion followed re-examination in September 2026; PHOENIX is planned as a global Phase 3 RCT versus prespecified BAT, subject to funding and regulatory clearance.

• PHOENIX targets FPI in H1 2027, LPI in H1 2029 and potential BLA in 2030.

MaaT033 in allo-HSCT

• PHOEBUS is an ongoing randomized, double-blind, placebo-controlled Phase 2b trial with 388 patients across 59 sites in six countries.

• Primary endpoint is overall survival at 12 months after allo-HSCT; LPI is expected in Q4 2027 and topline results in Q4 2028.

• The trial is designed to be pivotal, pending outcomes and final regulatory interactions; independent DSMB oversight has been in place since first patient inclusion.